These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 9424619)
1. [Macromolecular contrast media for MR mammography. A new approach to characterizing breast tumors]. Daldrup HE; Roberts TP; Mühler A; Gossmann A; Roberts HC; Wendland M; Rosenau W; Brasch RC Radiologe; 1997 Sep; 37(9):733-40. PubMed ID: 9424619 [TBL] [Abstract][Full Text] [Related]
3. Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. Saeed M; van Dijke CF; Mann JS; Wendland MF; Rosenau W; Higgins CB; Brasch RC J Magn Reson Imaging; 1998; 8(3):561-7. PubMed ID: 9626869 [TBL] [Abstract][Full Text] [Related]
4. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Daldrup-Link HE; Kaiser A; Helbich T; Werner M; Bjørnerud A; Link TM; Rummeny EJ Acad Radiol; 2003 Nov; 10(11):1237-46. PubMed ID: 14626298 [TBL] [Abstract][Full Text] [Related]
5. Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability. Roberts HC; Saeed M; Roberts TP; Mühler A; Shames DM; Mann JS; Stiskal M; Demsar F; Brasch RC J Magn Reson Imaging; 1997; 7(2):331-8. PubMed ID: 9090587 [TBL] [Abstract][Full Text] [Related]
6. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614 [TBL] [Abstract][Full Text] [Related]
7. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Daldrup-Link HE; Rydland J; Helbich TH; Bjørnerud A; Turetschek K; Kvistad KA; Kaindl E; Link TM; Staudacher K; Shames D; Brasch RC; Haraldseth O; Rummeny EJ Radiology; 2003 Dec; 229(3):885-92. PubMed ID: 14576446 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793 [TBL] [Abstract][Full Text] [Related]
9. MR imaging of the breast with Gd-DTPA enhancement: comparison with mammography and ultrasonography. Hachiya J; Seki T; Okada M; Nitatori T; Korenaga T; Furuya Y Radiat Med; 1991; 9(6):232-40. PubMed ID: 1668410 [TBL] [Abstract][Full Text] [Related]
10. Benign versus malignant breast disease: comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography. Fenlon HM; Phelan NC; O'Sullivan P; Tierney S; Gorey T; Ennis JT Radiology; 1997 Oct; 205(1):214-20. PubMed ID: 9314988 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Tofts PS; Berkowitz B; Schnall MD Magn Reson Med; 1995 Apr; 33(4):564-8. PubMed ID: 7776889 [TBL] [Abstract][Full Text] [Related]
12. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179 [TBL] [Abstract][Full Text] [Related]
13. [Value of MR tomography in inconclusive mammography findings]. Buchberger W; DeKoekkoek-Doll P; Obrist P; Dünser M Radiologe; 1997 Sep; 37(9):702-9. PubMed ID: 9424615 [TBL] [Abstract][Full Text] [Related]
14. Do mammography, sonography, and MR mammography have a diagnostic benefit compared with mammography and sonography? Müller-Schimpfle M; Stoll P; Stern W; Kurz S; Dammann F; Claussen CD AJR Am J Roentgenol; 1997 May; 168(5):1323-9. PubMed ID: 9129436 [TBL] [Abstract][Full Text] [Related]
15. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926 [TBL] [Abstract][Full Text] [Related]
17. Lesion characterization using vessel permeability map to new blood pool contrast agent calculated from dynamic magnetic resonance images. Kim S; Kim JH; Moon WK; Min BG J Digit Imaging; 2000 May; 13(2 Suppl 1):193-5. PubMed ID: 10847398 [TBL] [Abstract][Full Text] [Related]
18. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging. Kvistad KA; Rydland J; Vainio J; Smethurst HB; Lundgren S; Fjøsne HE; Haraldseth O Radiology; 2000 Aug; 216(2):545-53. PubMed ID: 10924584 [TBL] [Abstract][Full Text] [Related]
19. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner. Li X; Du X; Huo T; Liu X; Zhang S; Yuan F Acta Radiol; 2009 Jul; 50(6):583-94. PubMed ID: 19449236 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Boné B; Péntek Z; Perbeck L; Veress B Acta Radiol; 1997 Jul; 38(4 Pt 1):489-96. PubMed ID: 9240665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]